Two different industries are being sold under one label
"Longevity" and "peptide drugs" get used almost interchangeably in headlines, but they describe two very different investable realities:
- Metabolic peptide drugs — GLP-1 and GIP receptor agonists. These are real, FDA-approved medicines already generating tens of billions of dollars a year for Eli Lilly and Novo Nordisk, with a deep pipeline of challengers behind them. This is the part of the story with actual revenue today.
- True anti-aging pharmaceuticals. Compounds aimed at aging itself — senolytics, rapamycin analogs, NAD+ precursors and the rest — remain unapproved anywhere in the world for that purpose. Several of the field's highest-profile trials have missed their endpoints outright. This is the earlier, far riskier and largely unproven end of the story.
Conflating the two is where most of the hype comes from. The rest of this article treats them separately, because the risk profile of buying Eli Lilly stock and the risk profile of buying into an unproven longevity compound have almost nothing in common.
The size of the claim, and who's actually making it
Some investors and outlets have started describing longevity and metabolic biotech as a bigger opportunity than artificial intelligence — Forbes ran the headline "The New Billionaire Bet Isn't AI — It's Longevity Biotech" in June 2026, pointing to longevity biotech funding of roughly $3.74 billion in a single quarter, up 56% year over year. That is a real, sourced claim about where a slice of venture and billionaire capital is flowing — it is not the same as a settled forecast, and we are not asserting it as one.
The market-size numbers that are actually published, and who published them:
| Scope | Estimate | Source |
|---|---|---|
| Global obesity drug market | Up to $400 billion by 2030 in the bull case, $100 billion base case | Goldman Sachs Research |
| Global GLP-1 / type-2 diabetes and obesity market | ~$190 billion by 2035 | Morgan Stanley Research |
| GLP-1 drugs market (broader definition) | ~$132.8 billion by 2035 | Towards Healthcare market research |
| Broader "longevity economy" (health, wellness, finance, insurance, real estate combined) | ~$5.3 trillion (2023) growing toward ~$8 trillion by 2030 | Cited across multiple longevity-economy market reports |
Note the difference in scope on that last row: the trillion-dollar figures describe the entire longevity economy — insurance products, wellness real estate, diagnostics, financial planning — not the peptide-drug market specifically. The drug market itself, on every analyst estimate above, is sized in the tens to low hundreds of billions, not trillions. Both figures are real and sourced; they are just answering different questions, and headlines that borrow the bigger number to describe the drug market alone are overstating it.
The companies with real, approved revenue today
| Ticker | Company | What they have |
|---|---|---|
| LLY | Eli Lilly | Zepbound/Mounjaro (tirzepatide), FDA-approved, market-leading GLP-1/GIP franchise. |
| NVO | Novo Nordisk (ADR) | Ozempic/Wegovy (semaglutide), FDA-approved, the other half of the current duopoly. |
| AMGN | Amgen | MariTide (AMG133), a GLP-1 agonist/GIP-antagonist peptide in Phase 3 (MARITIME program) — not yet approved. |
| VKTX | Viking Therapeutics | VK2735, an oral and injectable dual GLP-1/GIP agonist in Phase 3 obesity trials (VANQUISH) — not yet approved. |
Lilly and Novo Nordisk are the only two names on this list with drugs actually approved and selling today. Amgen and Viking Therapeutics are real, well-funded, publicly traded companies with genuine Phase 3 data — but Phase 3 is not approval, and a disappointing trial readout can move either stock sharply. Viking Therapeutics' Phase 2 data showed up to 14.7% mean body-weight reduction at 13 weeks with no plateau observed — a real, company-reported result, and also only a mid-stage signal, not a Phase 3 confirmation.
See GLP-1 and obesity drug stocks for the full, continuously updated screen of every ticker in our universe carrying this tag.
Where true anti-aging drugs actually stand
If the reason you're interested is aging itself — not obesity or diabetes — the evidence picture is genuinely different, and worth reading before any of this shapes an investment decision. CureMed's clinical-pharmacy review team grades longevity compounds against human trial data rather than marketing claims, and their verdict is blunt: no drug is approved anywhere in the world to treat aging, and several of the field's highest-profile trials — a senolytic bone trial, the PEARL rapamycin trial, and a Phase 3 mTOR inhibitor study — have missed their endpoints or failed outright.
- Anti-aging pharmaceuticals: what has actually been tested in people — CureMed's evidence-graded review of every anti-aging drug candidate, including why the biggest geroscience trials have failed.
- Which longevity peptides are best for energy and recovery? — a separate class of peptides sold direct-to-consumer for energy and recovery, graded against controlled human evidence rather than marketing.
- The best longevity supplements, ranked by human evidence — where the non-prescription side of this market actually stands on proof.
That distinction matters for an investor, not just a patient: a company's stock can do well on obesity-drug revenue even while its aging-specific pipeline produces nothing that ever reaches approval. Read the company's actual approved indications, not the "longevity" framing in its investor materials.
Getting exposure to this theme
The straightforward route is owning the shares directly through a stockbroker — see healthcare stocks and best brokers for US stocks. For traders who want leveraged, short-term exposure to a single name's price around a trial readout or earnings date instead of a long-term position, that's available as a CFD through a non-US-regulated broker.
3,000+ share CFDs across US and global exchanges, $20 minimum.
Open a Capital.com account